The cash flow of IMMUNOVANT, INC. over the past 8 years
Chart IMMUNOVANT, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2019–2026 Open the chart →In fiscal 2026, the latest fiscal year on file, IMMUNOVANT, INC.'s operating cash flow was -$407.31M and its capital expenditures $8K, leaving free cash flow of -$407.32M. Free cash flow was below zero in all 8 years shown. It ranged from -$407.32M in fiscal 2026 to -$28.6M in fiscal 2019. Capital expenditures were highest in fiscal 2025, at $759K.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2026ended Mar 31, 2026 | -$407.31M | $8K | -$407.32M |
| 2025ended Mar 31, 2025 | -$375.87M | $759K | -$376.63M |
| 2024ended Mar 31, 2024 | -$214.23M | $360K | -$214.59M |
| 2023ended Mar 31, 2023 | -$188.19M | $197K | -$188.39M |
| 2022ended Mar 31, 2022 | -$106.11M | $254K | -$106.37M |
| 2021ended Mar 31, 2021 | -$83.33M | $210K | -$83.54M |
| 2020ended Mar 31, 2020 | -$53.36M | $31K | -$53.39M |
| 2019ended Mar 31, 2019 | -$28.55M | $52K | -$28.6M |
Fiscal years as IMMUNOVANT, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on IMMUNOVANT, INC.
- The profitability of IMMUNOVANT, INC.
- The debt of IMMUNOVANT, INC.
- All of IMMUNOVANT, INC.'s financials, charted
Companies of a similar size
- CVICVR ENERGY, INC
- EPRTEssential Properties Realty Trust, Inc.
- CACCCREDIT ACCEPTANCE CORP
- MKTXMARKETAXESS HOLDINGS INC
- TEXTerex Corporation
Not investment advice. This page shows what IMMUNOVANT, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.